Literature DB >> 2369789

Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

P E Lønning1.   

Abstract

Aminoglutethimide is an aromatase inhibitor that is successfully used for endocrine treatment of advanced breast cancer. This drug also stimulates the activity of hepatic mixed-function oxidases, increasing the metabolism of several drugs, including warfarin, digitoxin, antipyrine and theophylline. It also increases the plasma clearance rate of oestrone sulphate. As this oestrogen may be an important substrate for tumour cells, stimulation of oestrone sulphate metabolism may be a component of the mechanism of action of aminoglutethimide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369789     DOI: 10.1007/bf02897223

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  33 in total

1.  Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide.

Authors:  P E Lønning; P Skulstad
Journal:  J Steroid Biochem       Date:  1989-10       Impact factor: 4.292

2.  Assessment of antipyrine kinetics by measurement in saliva.

Authors:  H S Fraser; J C Mucklow; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

Review 3.  New endocrine drugs for treatment of advanced breast cancer.

Authors:  P E Lønning
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

4.  16-Hydroxylation of estrone-3-sulfate and estrone in the guinea pig in vivo.

Authors:  R Hobkirk; M Nilsen; J Mori
Journal:  Endocrinology       Date:  1978-10       Impact factor: 4.736

5.  Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.

Authors:  R J Santen; S Santner; B Davis; J Veldhuis; E Samojlik; E Ruby
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

6.  Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Authors:  R Cash; A J Brough; M N Cohen; P S Satoh
Journal:  J Clin Endocrinol Metab       Date:  1967-09       Impact factor: 5.958

7.  Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors:  P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

8.  In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.

Authors:  S J Santner; P D Feil; R J Santen
Journal:  J Clin Endocrinol Metab       Date:  1984-07       Impact factor: 5.958

9.  Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by reversed-phase liquid chromatography.

Authors:  J S Schanche; P E Lønning; P M Ueland; S Kvinnsland
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

10.  A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

Authors:  M Dowsett; A L Harris; R Stuart-Harris; M Hill; B M Cantwell; I E Smith; S L Jeffcoate
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

View more
  7 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 4.  Is there a growing role for endocrine therapy in the treatment of breast cancer?

Authors:  P E Lønning
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 5.  Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.

Authors:  Mark Sanford; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Aromatase inhibitors--where are we now?

Authors:  W R Miller
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

Review 7.  The Underrated Risks of Tamoxifen Drug Interactions.

Authors:  Philip D Hansten
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-10       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.